-
公开(公告)号：US08980290B2
公开(公告)日：2015-03-17
申请号：US12614216
申请日：2009-11-06
IPC分类号： A61K9/00 , A61K31/216 , A61K47/00 , A61K9/06 , A61K31/56 , A61K47/10 , A61K47/32 , A61K47/38
CPC分类号： A61K9/06 , A61K9/0014 , A61K31/216 , A61K31/56 , A61K47/10 , A61K47/32 , A61K47/38
摘要： The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.
摘要翻译： 本发明一般涉及经皮或经粘膜给药抗胆碱能药如奥昔布宁的组合物或制剂。 本发明利用新型的递送载体，并且是基本上不含有无臭和无刺激性的透皮制剂，其基本上不含长链脂肪醇，长链脂肪酸和长链脂肪酸酯。 公开了一种用于用这些制剂治疗患有尿失禁的受试者的方法，同时减少药物的峰值浓度和与口服抗胆碱能药物相关的不期望的副作用的发生率。
-
公开(公告)号：US08652491B2
公开(公告)日：2014-02-18
申请号：US13566900
申请日：2012-08-03
IPC分类号： A61K9/00 , A61K31/216 , A61K47/00
CPC分类号： A61K9/06 , A61K9/0014 , A61K31/216 , A61K31/56 , A61K47/10 , A61K47/32 , A61K47/38
摘要： The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.
摘要翻译： 本发明一般涉及经皮或经粘膜给药抗胆碱能药如奥昔布宁的组合物或制剂。 本发明利用新型的递送载体，并且是基本上不含有无臭和无刺激性的透皮制剂，其基本上不含长链脂肪醇，长链脂肪酸和长链脂肪酸酯。 公开了一种用于将这种制剂施用于有需要的人，同时减少了与口服抗胆碱能剂相关的药物峰浓度和不期望的副作用的发生率。
-
公开(公告)号：US20080260842A1
公开(公告)日：2008-10-23
申请号：US12147816
申请日：2008-06-27
摘要： A transdermal or topical skin-friendly composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.
摘要翻译： 一种透皮或局部皮肤友好的组合物，包括抗胆碱剂，例如奥昔布宁，含脲化合物和载体系统。 公开了用于治疗受试者尿失禁同时减少药物峰值浓度和与口服抗胆碱能药物相关的不良副作用的发生率的方法。
-
公开(公告)号：US20120294934A1
公开(公告)日：2012-11-22
申请号：US13566900
申请日：2012-08-03
IPC分类号： A61K47/10 , A61P25/00 , A61K47/16 , A61K9/127 , A61K47/28 , A61K47/24 , A61K31/216 , A61P31/04
CPC分类号： A61K9/06 , A61K9/0014 , A61K31/216 , A61K31/56 , A61K47/10 , A61K47/32 , A61K47/38
摘要： The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.
摘要翻译： 本发明一般涉及经皮或经粘膜给药抗胆碱能药如奥昔布宁的组合物或制剂。 本发明利用新型的递送载体，并且是基本上不含有无臭和无刺激性的透皮制剂，其基本上不含长链脂肪醇，长链脂肪酸和长链脂肪酸酯。 公开了一种用于将这种制剂施用于有需要的人，同时减少了与口服抗胆碱能剂相关的药物峰浓度和不期望的副作用的发生率。
-
公开(公告)号：US07470433B2
公开(公告)日：2008-12-30
申请号：US11693988
申请日：2007-03-30
摘要： The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
摘要翻译： 本发明一般涉及用于经皮或经粘膜施用活性剂如雌二醇的制剂。 本发明是基本上无臭和无刺激的透皮制剂，其基本上不含长链脂肪醇，长链脂肪酸和长链脂肪酸酯。
-
公开(公告)号：US07425340B2
公开(公告)日：2008-09-16
申请号：US11120306
申请日：2005-05-02
CPC分类号： A61K47/18 , A61K9/0014 , A61K9/06 , A61K9/7023 , A61K31/17 , A61K31/195 , A61K47/10 , Y10S514/818 , Y10S514/821 , A61K2300/00
摘要： A transdermal or topical composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects.
摘要翻译： 一种透皮或局部组合物，包括抗胆碱剂，例如奥昔布宁，含尿素化合物和载体系统。 公开了一种用于治疗受试者尿失禁同时减少药物峰值浓度和不良副作用的发生率的方法。
-
公开(公告)号：US08980309B2
公开(公告)日：2015-03-17
申请号：US13106530
申请日：2011-05-12
IPC分类号： A61F13/00 , A61K9/70 , A61K9/00 , A61K9/06 , A61K31/025 , A61K31/435 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38
CPC分类号： A61K9/7007 , A61K9/0014 , A61K9/006 , A61K9/06 , A61K31/025 , A61K31/435 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38 , Y10S514/946 , Y10S514/947
摘要： This invention relates to novel transdermal or transmucosal pharmaceutical formulation having an active agent of testosterone which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The solvent system of the formulation includes a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of the active agent in a pharmaceutical formulation.
摘要翻译： 本发明涉及具有睾丸激素活性剂的新型透皮或透粘膜药物制剂，其减少了其他个体的污染的发生和使用者的衣物的转移。 制剂的溶剂体系包括二乙二醇的单烷基醚和特定比例的二醇，以及水和醇的混合物。 本发明还涉及抑制或延迟药物制剂中活性剂结晶的方法。
-
8.发明申请Pharmaceutical compositions with melting point depressant agents and method of making same 审中-公开具有熔点抑制剂的药物组合物及其制备方法公开(公告)号：US20070048360A1
公开(公告)日：2007-03-01
申请号：US11506368
申请日：2006-08-17
申请人： Dario R. Carrara , Arnaud Grenier , Ingo Alberti , Christelle Rogue , Celine Besse , Henry Laetitia
发明人： Dario R. Carrara , Arnaud Grenier , Ingo Alberti , Christelle Rogue , Celine Besse , Henry Laetitia
摘要： The invention relates to the use of chemical fragrance ingredient to lower the melting point of active agents, thereby changing crystalline active agents into an amorphous state. The invention also relates to methods of enhancing the transdermal or transmucosal skin permeation or skin penetration of pharmacologically active agents to patients in need thereof. The compositions of the present invention present the additional benefits of being substantially alcohol-free and having a pleasant olfactory profile.
摘要翻译： 本发明涉及使用化学香料成分来降低活性剂的熔点，从而将结晶活性剂改变成无定形状态。 本发明还涉及增强药理学活性剂对有需要的患者的透皮或经粘膜皮肤渗透或皮肤渗透的方法。 本发明的组合物具有基本上无醇且具有令人愉悦的嗅觉特征的额外益处。
-
9.发明申请Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents 审中-公开渗透增强剂，其包含姜黄或锗酸根用于透皮和局部施用活性剂公开(公告)号：US20050244522A1
公开(公告)日：2005-11-03
申请号：US11114537
申请日：2005-04-26
IPC分类号： A61K9/00 , A61K9/70 , A61K31/121 , A61K47/10 , A61K47/32 , A61K47/38 , A61K47/46 , A61K35/78
CPC分类号： A61K9/0014 , A61K31/121 , A61K36/9066 , A61K47/10 , A61K47/32 , A61K47/38 , A61K47/46 , A61K2300/00
摘要： A formulation, method and system for the topical, transdermal or transmucosal administration of a therapeutically effective active agent. Particularly, the invention provides a formulation, system and method for enhancing the permeation or penetration of active agents across the dermal or mucosal surfaces of a mammalian subject. The formulation includes a plant extract of the genus Curcuma of the family Zingiberaceae, a germacrone, or a natural or synthetic constituent thereof, which has been found to increase penetration of the active agent across the dermal or mucosal surface. If desired, a secondary permeation enhancer of a polyalcohol, a monoalkyl ether of diethylene glycol, a tetraglycol, or a mixture thereof can be used for certain active agents for optimal permeation enhancement.
摘要翻译： 用于局部，透皮或经粘膜给药治疗有效活性剂的制剂，方法和系统。 特别地，本发明提供了用于增强活性剂穿过哺乳动物受试者的皮肤或粘膜表面的渗透或渗透的制剂，系统和方法。 该制剂包括姜科科植物的姜黄属植物提取物，锗菌属或其天然或合成成分，其已被发现增加了活性剂穿过皮肤或粘膜表面的渗透。 如果需要，可以使用多元醇的二次渗透增强剂，二甘醇的单烷基醚，四甘醇或其混合物，用于某些活性剂以获得最佳的渗透增强作用。
-
公开(公告)号：US20110257141A1
公开(公告)日：2011-10-20
申请号：US13106530
申请日：2011-05-12
IPC分类号： A61K31/568
CPC分类号： A61K9/7007 , A61K9/0014 , A61K9/006 , A61K9/06 , A61K31/025 , A61K31/435 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38 , Y10S514/946 , Y10S514/947
摘要： This invention relates to novel transdermal or transmucosal pharmaceutical formulation having an active agent of testosterone which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The solvent system of the formulation includes a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of the active agent in a pharmaceutical formulation.
摘要翻译： 本发明涉及具有睾丸激素活性剂的新型透皮或透粘膜药物制剂，其减少了其他个体的污染的发生和使用者的衣物的转移。 制剂的溶剂体系包括二乙二醇的单烷基醚和特定比例的二醇，以及水和醇的混合物。 本发明还涉及抑制或延迟药物制剂中活性剂结晶的方法。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.018 秒)
